Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Operating Expenses (2022 - 2025)

ARS Pharmaceuticals' Other Operating Expenses history spans 4 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 611.45% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $20.4 million, up 1990.38%, while the annual FY2025 figure was $20.4 million, 1990.38% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $6.2 million at ARS Pharmaceuticals, down from $8.2 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $13.0 million in Q2 2022 and bottomed at -$11.8 million in Q3 2022.
  • The 4-year median for Other Operating Expenses is $3.0 million (2022), against an average of $2.7 million.
  • The largest annual shift saw Other Operating Expenses surged 486400.0% in 2022 before it skyrocketed 611.45% in 2025.
  • A 4-year view of Other Operating Expenses shows it stood at -$1000.0 in 2021, then soared by 486400.0% to $4.9 million in 2022, then plummeted by 82.21% to $865000.0 in 2024, then surged by 611.45% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Other Operating Expenses are $6.2 million (Q4 2025), $8.2 million (Q3 2025), and $5.0 million (Q2 2025).